The risky business of dopamine agonists in Parkinson disease and impulse control disorders

Behavioral Neuroscience

Volumn 125, Issue 4, 2011, Pages 492-500

  Claassen, Daniel O ^a   van den Wildenberg, Wery P M ^b   Ridderinkhof, K Richard ^b   Jessup, Charles K ^a   Harrison, Madaline B ^a   Wooten, G Frederick ^a   Wylie, Scott A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Dopamine agonists; Impulse control disorders; Parkinson's disease; Risk behavior

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PRAMIPEXOLE; ROPINIROLE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPULSION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG MEGADOSE; FEEDING BEHAVIOR; FEMALE; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; LOW DRUG DOSE; MALE; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; RISK ASSESSMENT; RISK REDUCTION; SHOPPING; TASK PERFORMANCE; THERAPY EFFECT;

AGED; DOPAMINE AGONISTS; FEMALE; GAMBLING; HUMANS; IMPULSE CONTROL DISORDERS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; RISK FACTORS; RISK-TAKING; SEVERITY OF ILLNESS INDEX; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 79960938723     PISSN: 07357044     EISSN: 19390084     Source Type: Journal    
DOI: 10.1037/a0023795     Document Type: Article

References (42)

1. Berridge K.C. The debate over dopamine's role in reward: The case for incentive salience. Psychopharmacology 2007, 191(3):391-431.
2. Black K.J., Hershey T., Koller J.M., Videen T.O., Mintun M.A., Price J.L., Perlmutter J.S. A possible substrate for dopamine-related changes in mood and behavior: Prefrontal and limbic effects of a D3-preferring dopamine agonist. Proceedings of the National Academy of Sciences, USA 2002, 99(26):17113-17118.
3. Bostwick J.M., Hecksel K.A., Stevens S.R., Bower J.H., Ahlskog J.E. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic parkinson disease. Mayo Clinic Proceedings 2009, 84(4):310-316.
4. Cools R., Barker R.A., Sahakian B.J., Robbins T.W. Enhanced or impaired cognitive function in parkinson's disease as a function of dopaminergic medication and task demands. Cerebral Cortex 2001, 11(12):1136-1143.
5. Dodd M.L., Klos K.J., Bower J.H., Geda Y.E., Josephs K.A., Ahlskog J.E. Pathological gambling caused by drugs used to treat parkinson disease. Archives of Neurology 2005, 62(9):1377-1381.
6. Evans A.H., Katzenschlager R., Paviour D., O'Sullivan J.D., Appel S., Lawrence A.D., Lees A.J. Punding in parkinson's disease: Its relation to the dopamine dysregulation syndrome. Movement Disorders 2004, 19(4):397-405.
7. Fearnley J.M., Lees A.J. Ageing and parkinson's disease: Substantia nigra regional selectivity. Brain 1991, 114(Pt. 5):2283-2301.
8. Fiorillo C.D., Tobler P.N., Schultz W. Discrete coding of reward probability and uncertainty by dopamine neurons. Science March 2003, 299(5614):1898-1902.
9. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975, 12(3):189-198.
10. Frank M.J., Seeberger L.C., O'reilly R.C. By carrot or by stick: Cognitive reinforcement learning in parkinsonism. Science November 2004, 306(5703):1940-1943.
11. Gallagher D.A., O'Sullivan S.S., Evans A.H., Lees A.J., Schrag A. Pathological gambling in parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series. Movement Disorders 2007, 22(12):1757-1763.
12. Guthrie M., Myers C.E., Gluck M.A. A neurocomputational model of tonic and phasic dopamine in action selection: A comparison with cognitive deficits in parkinson's disease. Behavioural Brain Research 2009, 200(1):48-59.
13. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic parkinson's disease: A clinico-pathological study of 100 cases. Journal of Neurology Neurosurg Psychiatry 1992, 55(3):181-184.
14. Hunt M.K., Hopko D.R., Bare R., Lejuez C.W., Robinson E.V. Construct validity of the balloon analog risk task (BART): Associations with psychopathy and impulsivity. Assessment 2005, 12(4):416-428.
15. Jackson D.N., Hourany L., Vidmar N.J. A four-dimensional interpretation of risk taking. Journal of Personality 1972, 40(3):483-501.
16. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic parkinson's disease. pathophysiologic and clinical implications. The New England Journal of Medicine 1988, 318(14):876-880.
17. Lee T.M., Guo L.G., Shi H.Z., Li Y.Z., Luo Y.J., Sung C.Y., Lee T.M. Neural correlates of traditional chinese medicine induced advantageous risk-taking decision making. Brain and Cognition 2009, 71(3):354-361.
18. Leigh B.C. Peril, chance, adventure: Concepts of risk, alcohol use and risky behavior in young adults. Addiction 1999, 94(3):371-383.
19. Lejuez C.W., Aklin W., Daughters S., Zvolensky M., Kahler C., Gwadz M. Reliability and validity of the youth version of the balloon analogue risk task (BART-Y) in the assessment of risk-taking behavior among inner-city adolescents. Journal of Clinical Child and Adolescent Psychology 2007, 36(1):106-111.
20. Lejuez C.W., Aklin W.M., Jones H.A., Richards J.B., Strong D.R., Kahler C.W., Read J.P. The balloon analogue risk task (BART) differentiates smokers and nonsmokers. Experimental and Clinical Psychopharmacology 2003, 11(1):26-33.
21. Lejuez C.W., Aklin W.M., Zvolensky M.J., Pedulla C.M. Evaluation of the balloon analogue risk task (BART) as a predictor of adolescent real-world risk-taking behaviours. Journal of Adolescence 2003, 26(4):475-479.
22. Lejuez C.W., Read J.P., Kahler C.W., Richards J.B., Ramsey S.E., Stuart G.L., Brown R.A. Evaluation of a behavioral measure of risk taking: The balloon analogue risk task (BART). Journal of Experimental Psychology: Applied 2002, 8(2):75-84.
23. Leland D.S., Paulus M.P. Increased risk-taking decision-making but not altered response to punishment in stimulant-using young adults. Drug and Alcohol Dependence 2005, 78(1):83-90. doi: 10.1016/j.drugalcdep.2004.10.001.
24. Merims D., Freedman M. Cognitive and behavioural impairment in parkinson's disease. International Review of Psychiatry 2008, 20(4):364-373.
25. Pontone G., Williams J.R., Bassett S.S., Marsh L. Clinical features associated with impulse control disorders in parkinson disease. Neurology 2006, 67(7):1258-1261.
26. Radloff L.S. The CES-D scale: A self-report depression scale for research in the general population. Applied Psychological Measurement 1977, 1(3):385-401.
27. Rao H., Korczykowski M., Pluta J., Hoang A., Detre J.A. Neural correlates of voluntary and involuntary risk taking in the human brain: An fMRI study of the balloon analogue risk task (BART). NeuroImage 2008, 42:902-910.
28. Rao H., Mamikonyan M.S., Detre J.A., Sideowf A.D., Stern M.B., Potenza M.N., Weintraub D. Decreased ventral striatal activity with impulse control disorders in parkinson's disease. Movement Disorders 2010, 25:1660-1669.
29. Riba J., Kramer U.M., Heldmann M., Richter S., Munte T.F. Dopamine agonist increases risk taking but blunts reward-related brain activity. PLoS One 2008, 3(6):1-5.
30. Sanfey A.G., Chang L.J. Multiple systems in decision making. Annals of the New York Academy of Sciences 2008, 1128:53-62.
31. Steeves T.D.L., Miyasaki J., Zurowski M., Lang A.E., Pellecchia G., van Eimeren T.V., Strafella A.P. Increased striatal dopamine release in parkinsonian patients with pathological gambling: A [11C] raclopride PET study. Brain 2009, 132:1376-1385.
32. St Onge J.R., Chiu Y.C., Floresco S.B. Differential effects of dopaminergic manipulations on risky choice. Psychopharmacology 2010, 211(2):209-221.
33. Swainson R., Rogers R.D., Sahakian B.J., Summers B.A., Polkey C.E., Robbins T.W. Probabilistic learning and reversal deficits in patients with parkinson's disease or frontal or temporal lobe lesions: Possible adverse effects of dopaminergic medication. Neuropsychologia 2000, 38(5):596-612.
34. Thiel A., Hilker R., Kessler J., Habedank B., Herholz K., Heiss W.D. Activation of basal ganglia loops in idiopathic parkinson's disease: A PET study. Journal of Neural Transmission 2003, 110(11):1289-1301.
35. van Eimeren T., Ballanger B., Pellecchia G., Miyasaki J.M., Lang A.E., Strafella A.P. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: A trigger for pathological gambling in parkinson's disease?. Neuropsychopharmacology 2009, 34(13):2758-2766.
36. van Eimeren T., Pellecchia G., Cilia R., Ballanger B., Steeves T.D., Houle S., Strafella A.P. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology 2010, 75:1711-1716.
37. Voon V., Hassan K., Zurowski M., de Souza M., Thomsen T., Fox S., Miyasaki J. Prevalence of repetitive and reward-seeking behaviors in parkinson disease. Neurology 2006, 67(7):1254-1257.
38. Voon V., Pessiglione M., Brezing C., Gallea C., Fernandez H.H., Dolan R.J., Hallett M. Mechanisms underlying dopaminemediated reward bias in compulsive behaviors. Neuron 2010, 65:135-142.
39. Voon V., Potenza M.N., Thomsen T. Medication-related impulse control and repetitive behaviors in parkinson's disease. Current Opinion in Neurology 2007, 20(4):484-492.
40. Weintraub D., Hoops S., Shea J.A., Lyons K.E., Pahwa R., Driver-Dunckley E.D., Voon V. Validation of the questionnaire for impulsive-compulsive disorders in parkinson's disease. Movement Disorders 2009, 24(10):1461-1467.
41. Weintraub D., Koester J., Potenza M.N., Siderowf A.D., Stacy M., Voon V., Lang A.E. Impulse control disorders in parkinson disease: A cross-sectional study of 3090 patients. Archives of Neurology 2010, 67(5):589-595.
42. Weintraub D., Siderowf A.D., Potenza M.N., Goveas J., Morales K.H., Duda J.E., Stern M.B. Association of dopamine agonist use with impulse control disorders in parkinson disease. Archives of Neurology 2006, 63(7):969-973.